---
title: "HUTCHMED: The new drug application for the combination therapy of Roflumilast and Sintilimab has been accepted"
description: "HUTCHMED announced that the new drug application for the combination therapy of furmonertinib and sintilimab has been accepted by the National Medical Products Administration of China, applicable to p"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260829506.md"
published_at: "2025-10-13T04:07:46.000Z"
---

# HUTCHMED: The new drug application for the combination therapy of Roflumilast and Sintilimab has been accepted

> HUTCHMED announced that the new drug application for the combination therapy of furmonertinib and sintilimab has been accepted by the National Medical Products Administration of China, applicable to patients with locally advanced or metastatic renal cell carcinoma who have previously failed systemic therapy. The Phase III results of the study will be presented on October 17 at the European Society for Medical Oncology Annual Meeting. Furmonertinib has been approved in China for the treatment of various cancers

HUTCHMED (00013.HK) announced the results of the FRUSICA-2 registration study of fruquintinib in combination with sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma. The results of the Phase III portion of the study will be presented on October 17 at the European Society for Medical Oncology (ESMO) annual meeting in Berlin, Germany.

The company stated that based on the data from the FRUSICA-2 study, the National Medical Products Administration of China has accepted the new drug application for the combination therapy of fruquintinib and sintilimab for patients with locally advanced or metastatic renal cell carcinoma who have previously failed systemic therapy.

Currently, fruquintinib has been approved in China for use in patients who have previously received fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, as well as for patients with metastatic colorectal cancer who have previously received or are unsuitable for anti-vascular endothelial growth factor (VEGF) therapy and anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type). The combination therapy of fruquintinib and sintilimab has been conditionally approved in China for patients with advanced mismatch repair proficient (pMMR) endometrial cancer who have failed previous systemic anti-tumor therapy and are unsuitable for curative surgical treatment or radical radiotherapy

### Related Stocks

- [HCM.US - Hutchmed China](https://longbridge.com/en/quote/HCM.US.md)
- [00013.HK - HUTCHMED](https://longbridge.com/en/quote/00013.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 和黃醫藥的藥物獲得中國優先審評資格，用於治療膽管癌 | 和黃醫藥（Hutchmed China Ltd）宣佈，中國監管機構已接受其癌症治療藥物 fanregratinib 的新藥申請，並授予其優先審評狀態。該藥物針對具有 FGFR2 基因改變的晚期肝內膽管癌患者。該申請得到了成功的二期研究的支持 | [Link](https://longbridge.com/en/news/270984953.md) |
| 積極的中國試驗數據使和黃醫藥在 2026 年更接近於提交罕見血液疾病藥物的申請 | 和黃醫藥公佈了 sovleplenib 在自身免疫性貧血的第三階段臨牀試驗的積極結果，支持計劃於 2026 年在中國提交藥物申請。該試驗達到了主要終點，顯示出在温抗體自身免疫性溶血性貧血（wAIHA）患者中具有持久的血紅蛋白反應。和黃醫藥計 | [Link](https://longbridge.com/en/news/271806067.md) |
| 長假期利好遊戲股 網易或符雙重主要上市標準 大行看好心動公司 | 長假期利好遊戲股，網易（9999）去年第四季盈利下滑，但股價已反映情況，適合撈底。心動公司（2400）中期盈利增長強勁。網易全年純利 337.6 億元，股東權益回報率 21%。網易有望符合港交所雙重主要上市標準，若成功將可納入滬深港通。新春 | [Link](https://longbridge.com/en/news/276402845.md) |
| 股票分析師協會料港股短期較波動 恒指有望見 32000 點 | 香港股票分析師協會主席鄧聲興表示，短期內港股可能較波動，但對市場保持樂觀，預計恆指有望達到 31000 至 32000 點。成交量至關重要，需維持在 2500 億至 3000 億水平。投資者需警惕 AI 板塊的估值風險，資源板塊，特別是貴金 | [Link](https://longbridge.com/en/news/276410701.md) |
| 美國與印尼敲定貿易協議 輸美商品關税降至 19% | 美國與印尼達成貿易協議，印尼輸美商品關税降至 19%。協議於去年 7 月宣佈，印尼在協議前面臨高達 32% 的關税威脅。協議內容包括豁免美國企業遵守自製率規定，並解決美國農產品在印尼的貿易障礙。此外，印尼同意採購價值 330 億美元的美國能 | [Link](https://longbridge.com/en/news/276423471.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.